A Phase II Clinical Trial Assessing the Safety, Tolerability, and Pharmacokinetics of LTC004 in Combination With MIL-97 ± Chemotherapy in Patients With Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 28 Feb 2024
Price :
$35 *
At a glance
- Drugs LTC-004 (Primary) ; Antineoplastics; MIL 97
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions
- 16 Feb 2024 New trial record